AP2A2 and Alzheimer disease: We used this hypothesis validation workflow to filter the list of 29 candidate targets to five top‐tier targets that both impact relevant phenotypes and induce proteomic changes that reverse AD‐associated signatures: AP2A2, PDHB, PDHA1, DLAT, and PSMC3.